Biogen's revenues in the fourth quarter are likely to have been hurt by lower sales of its multiple sclerosis ("MS") drugs like Tecfidera and Tysabri and rising competitive pressure in the MS market. Tecfidera sales have been declining as multiple generic versions of the drug have been launched in the United States.